<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985582</url>
  </required_header>
  <id_info>
    <org_study_id>SEA032</org_study_id>
    <nct_id>NCT00985582</nct_id>
  </id_info>
  <brief_title>Antiviral Therapy for Influenza A H1N1</brief_title>
  <acronym>SEA032</acronym>
  <official_title>Antiviral Treatment in Adults and Children With Novel Influenza A (H1N1) Respiratory Tract Infection - a Clinical, Virological and Pharmacokinetic Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South East Asia Infectious Disease Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>South East Asia Infectious Disease Clinical Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to characterise the clinical efficacy and virological clearance&#xD;
      dynamics of orally administered oseltamivir in patients with influenza caused by novel&#xD;
      influenza A(H1N1). This research will also contribute to enhancing research capacity in&#xD;
      affected countries.&#xD;
&#xD;
      The objectives are to assess the:&#xD;
&#xD;
        -  viral replication levels over time in affected patients&#xD;
&#xD;
        -  antiviral efficacy of oral oseltamivir&#xD;
&#xD;
        -  patterns and compartments of viral shedding, tissue distribution&#xD;
&#xD;
        -  innate inflammatory response and relation to viral replication&#xD;
&#xD;
        -  kinetics of antibody response&#xD;
&#xD;
        -  antiviral sensitivity of influenza viruses at baseline and during oseltamivir treatment&#xD;
           using in vitro and molecular methods&#xD;
&#xD;
        -  pharmacokinetic characteristics of oseltamivir and oseltamivir carboxylate&#xD;
&#xD;
        -  all cause in hospital mortality&#xD;
&#xD;
        -  clinical and radiological features, disease course and outcome&#xD;
&#xD;
        -  length of stay in hospital&#xD;
&#xD;
        -  risk factors associated with development of severe disease and death&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Any patient over 1 year of age who presents to a participating institution with confirmed&#xD;
      influenza A and who meets the study inclusion/exclusion criteria may be approached for&#xD;
      informed consent. Choice of antiviral is up to the study physician. Children aged 1-6 years&#xD;
      and asthmatics should receive oseltamivir. The weight- and age-adjusted dosage used will be&#xD;
      that approved for treatment of uncomplicated seasonal influenza, and doses will be&#xD;
      administered twice daily for 5 days for patients with normal renal function. All patients who&#xD;
      are clinical and/or virologic failures at day 5 will be treated for an additional 5 days of&#xD;
      antivirals. After coming off antiviral therapy patients can be discharged at day 10 if deemed&#xD;
      ready by study physicians and they are virologically negative.&#xD;
&#xD;
      During the course of treatment study evaluations will be performed to determine primary&#xD;
      efficacy end points including viral clearance on Day 5 on all collected nasopharyngeal&#xD;
      samples, assessed by RT PCR for novel H1N1 influenza AND no clinical features of clinical&#xD;
      failure. Evaluations will also be performed to determine secondary viral, serological,&#xD;
      clinical efficacy, safety and pharmacokinetic endpoints.&#xD;
&#xD;
      Patients will be followed up for up to 6 months after discharge for a clinical assessment,&#xD;
      pulmonary function and outcome of pregnancy.&#xD;
&#xD;
      The protocol will be reviewed after 6 months from starting or after 100 patients with&#xD;
      Influenza A are recruited.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Viral clearance on Day 5 on all collected nasopharyngeal samples, assessed by RT PCR for new influenza A(H1N1)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral clearance on Day 1, 2, 3, 4, 5 (H1N1) on nose and throat swab, assessed by RT PCR.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">181</enrollment>
  <condition>Influenza A Virus Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal swabs, throat swabs, nasopharyngeal aspirates, rectal swabs, urine, blood, will be&#xD;
      obtained for virological analyses, according to the age group specific study schedules&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a single arm clinical and virological study assessing the use of oral oseltamivir&#xD;
        or other agents in the treatment of patients with novel influenza A(H1N1) infection.&#xD;
&#xD;
        Any patient over 1 year of age with confirmed novel influenza A(H1N1) in whom appropriate&#xD;
        informed consent to collect data and samples is obtained. The protocol will be reviewed&#xD;
        after 6 months from starting or after 100 patients with new influenza A(H1N1) are&#xD;
        recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults, including pregnant and breast feeding women, and Children aged â‰¥ 12 months&#xD;
             when first seen with an acute febrile respiratory tract illness (ARI) of any severity&#xD;
             and influenza A, virologically proven on a respiratory specimen according to hospital&#xD;
             procedure, which is suspected to be novel influenza A(H1N1)&#xD;
&#xD;
          -  A positive influenza A H1 swine screening reverse transcriptase polymerase chain&#xD;
             reaction (RT PCR) or conventional PCR assay on one respiratory specimen : NPA, NP&#xD;
             swab, nasal wash, nasal swab and throat swab&#xD;
&#xD;
          -  Underlying illnesses including HIV&#xD;
&#xD;
          -  Prescribed oseltamivir prior to presentation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Farrar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Clinical Research Unit Ho Chi Minh City Vietnam</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute for Infectious and Tropical Diseases (NIITD), Viet Nam</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008 Dec;21(6):626-38. doi: 10.1097/QCO.0b013e3283199797. Review.</citation>
    <PMID>18978531</PMID>
  </reference>
  <reference>
    <citation>Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol. 2008 Jan;41(1):13-9. Epub 2007 Dec 11. Review.</citation>
    <PMID>18055254</PMID>
  </reference>
  <reference>
    <citation>Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis. 2003 Jul 1;188(1):57-61. Epub 2003 Jun 23.</citation>
    <PMID>12825171</PMID>
  </reference>
  <reference>
    <citation>Hurt AC, Ho HT, Barr I. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev Anti Infect Ther. 2006 Oct;4(5):795-805. Review.</citation>
    <PMID>17140356</PMID>
  </reference>
  <reference>
    <citation>Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf. 2003;26(11):787-801. Review.</citation>
    <PMID>12908848</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <last_update_submitted>May 25, 2011</last_update_submitted>
  <last_update_submitted_qc>May 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Jeremy Farrar FRCP Dphil / Principal Investigator</name_title>
    <organization>Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam</organization>
  </responsible_party>
  <keyword>Influenza A Virus (H1N1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

